The role of GD2 as a diagnostic and prognostic tumor marker in neuroblastoma (literature review)

Neuroblastoma (NB) is a rare malignant tumor characterized by highly variable biological behavior, including spontaneous and induced regression, maturation, and progression. To assess the prognosis and response to therapy in NB, the determination of a number of oncological markers is used, such as neuron-specific enolase, lactate dehydrogenase, ferritin. Nevertheless, the models for assessing the prognosis developed so far do not fully predict the specificity of the course of the disease. In this regard, the creation of methods for monitoring tumor status in real time, based on the analysis of circulating tumor biomarkers, seems to be extremely urgent. A characteristic feature of NB is the expression of various gangliosides on the surface of tumor cells. In particular, the content of disialoganglioside GD2 reaches up to 30 % of all gangliosides. At the same time, the level of GD2 expression depends on the differentiation of neurogenic tumors: the highest concentrations are determined on NB cells, the lowest – on ganglioneuroblastoma and ganglioneuroma. The phenomenon of “shedding”, the so-called flushing, of GD2 from the NB cell membrane made it possible to estimate its concentration in the peripheral bloodstream. The article discusses the evolutionary path of the methodology for detecting GD2 in blood serum, with an emphasis on the recently introduced liquid chromatography/ tandem mass spectrometry technique, which can be used as a starting point for the emergence of GD2 as a soluble biomarker of the tumor process, which is undoubtedly a powerful application in the clinical practice that offers hope for improved diagnosis, prognosis and riskadapted therapy strategies based on well-defined, measurable determinants in accordance with the concept of evidence-based medicine.

1. Spix C., Pastore G., Sankila R., Stiller C.A., Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2081–91. doi:10.1016/j.ejca.2006.05.008. PMID:16919772.

2. Matthay K.K., Maris J.M., Schleiermacher G., Nakagawara A., Mackall C.L., Diller L., Weiss W.A. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078. doi:10.1038/nrdp.2016.78. PMID:27830764.

3. Berthold F., Spix C., Kaatsch P., Lampert F. Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979–2015. Paediatr Drugs. 2017;19(6):577–93. doi:10.1007/s40272-017-0251-3. PMID:28786082.

4. Park J.R., Bagatell R., London W.B., Maris J.M., Cohn S.L., Mattay K.K., Hogarty M.; COG Neuroblastoma Committee. Childrenʼs Oncology Groupʼs 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60(6):985–93. doi:10.1002/pbc.24433.

5. Ladenstein R., Ambros I.M., Pötschger U., Amann G., Urban C., Fink F.M., Schmitt K., Jones R., Slociak M., Schilling F., Ritter J., Berthold F., Gadner H., Ambros P.F. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol. 2001;36(1):83–92. doi:10.1002/1096-911X(20010101)36:1<83::AID-MPO1020>3.0.CO;2-9. PMID:11464912.

6. Simon T., Spitz R., Faldum A., Hero B., Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol. 2004;26(12):791–6. PMID:15591897.

7. Petrov I., Suntsova M., Ilnitskaya E., Roumiantsev S., Sorokin M., Garazha A., Spirin P., Lebedev T., Gaifullin N., Larin S., Kovalchuk O., Konovalov D., Prassolov V., Roumiantsev A., Buzdin A. Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas. Oncotarget. 2017;8(48):83768–80. doi:10.18632/oncotarget.19662. PMID:29137381.

8. Wu Z.L., Schwartz E., Seeger R., Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986;46(1):440–3. PMID:3940209.

9. Fleurence J., Fougeray S., Bahri M., Cochonneau D., Clémenceau B., Paris F., Heczey A., Birklé S. Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. J Immunol Res. 2017;2017:5604891. doi:10.1155/2017/5604891.

10. Svennerholm L. Chromatographic separation of human brain gangliosides. J Neurochem. 1963;10:613–23. doi:10.1111/j.1471-4159.1963.tb08933.x. PMID:14066623.

11. Lopez P.H., Schnaar R.L. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol. 2009;19(5):549–57. doi:10.1016/j.sbi.2009.06.001.

12. Schulz G., Cheresh D.A., Varki N.M., Yu A., Staffileno L.K., Reisfeld R.A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44(12 Pt 1):5914–20. PMID:6498849.

13. Kolter T. Ganglioside biochemistry. ISRN Biochem. 2012;2012:506160. doi:10.5402/2012/506160. PMID:25969757.

14. Sariola H., Terävä H., Rapola J., Saarinen U.M. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. Am J Clin Pathol. 1991;96(2):248–52. doi:10.1093/ajcp/96.2.248. PMID:1713742.

15. Portoukalian J., David M.J., Gain P., Richard M. Shedding of GD2 ganglioside in patients with retinoblastoma. Int J Cancer. 1993;53(6):948–51. doi:10.1002/ijc.2910530614.

16. Suzuki M., Cheung N.K. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets. 2015;19(3):349–62. doi:10.1517/14728222.2014.986459.

17. Sait S., Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017;17(10):889–904. doi:10.1080/14737140.2017.1364995.

18. Yu R.K., Tsai Y.T., Ariga T., Yanagisawa M. Structures, biosynthesis, and functions of gangliosides--an overview. J Oleo Sci. 2011;60(10):537–44. doi:10.5650/jos.60.537. PMID:21937853.

19. Berois N., Osinaga E. Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies. Front Oncol. 2014;4:114. doi:10.3389/fonc.2014.00114. PMID:24904828.

20. Balis F.M., Busch C.M., Desai A.V., Hibbitts E., Naranjo A., Bagatell R., Irwin M., Fox E. The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma. Pediatr Blood Cancer. 2020;67(1):e28031. doi:10.1002/pbc.28031.

21. Kholodenko I.V., Kalinovsky D.V., Doronin I.I., Deyev S.M., Kholodenko R.V. Neuroblastoma Origin and Therapeutic Targets for Immunotherapy. J Immunol Res. 2018;2018:7394268. doi:10.1155/2018/7394268. PMID:30116755.

22. Busch C.M., Desai A.V., Moorthy G.S., Fox E., Balis F.M. A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, GD2, in human plasma or serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1102–1103:60–5. doi:10.1016/j.jchromb.2018.10.010.

23. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., Shimada H., Grupp S.A., Seeger R., Reynolds C.P., Buxton A., Reisfeld R.A., Gillies S.D., Cohn S.L., Maris J.M., Sondel P.M.; Childrenʼs Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34. doi:10.1056/NEJMoa0911123.

24. Shamanskaya T.V., Andreeva N.A., Utalieva D.T., Kachanov D.Yu. Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2020;19(3):173–88. (In Russ.). doi:10.24287/1726-1708-2020-19-3-173-188.

25. Yoshida S., Fukumoto S., Kawaguchi H., Sato S., Ueda R., Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 2001;61(10):4244–52. PMID:11358851.

26. Shibuya H., Hamamura K., Hotta H., Matsumoto Y., Nishida Y., Hattori H., Furukawa K., Ueda M., Furukawa K. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 2012;103(9):1656–64. doi:10.1111/j.1349-7006.2012.02344.x.

27. Furukawa K., Hamamura K., Ohkawa Y., Ohmi Y., Furukawa K. Disialyl gangliosides enhance tumor phenotypes with differential modalities. Glycoconj J. 2012;29(8–9):579–84. doi:10.1007/s10719-012-9423-0.

28. Ladisch S., Kitada S., Hays E.F. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest. 1987;79(6):1879–82. doi:10.1172/JCI113031. PMID:3584474.

29. Ladisch S., Ulsh L., Gillard B., Wong C. Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. J Clin Invest. 1984;74(6):2074–81. doi:10.1172/JCI111631. PMID:6511916.

30. Diatlovitskaia E.V., Kliuchareva E.V., Matveeva V.A., Sinitsyna E.V., Akhmed-Zade A.Sh. Effect of gangliosides on the cytotoxic activity of natural killers from Syrian hamsters. Biokhimiia. 1985;50(9):1514–6. PMID:4052509.

31. Ladisch S., Wu Z.L. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma. Lancet. 1985;1(8421):136–8. doi:10.1016/s0140-6736(85)91906-3. PMID:2857215.

32. Ladisch S., Wu Z.L., Feig S., Ulsh L., Schwartz E., Floutsis G., Wiley F., Lenarsky C., Seeger R. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer. 1987;39(1):73–6. doi:10.1002/ijc.2910390113. PMID:3539825.

33. Barkal A., Di Cesare J.L. Influence of sialic acid groups on the retention of glycosphingolipids in blood plasma. Biochim Biophys Acta. 1975;398(2):287–93. doi:10.1016/0005-2760(75)90144-7. PMID:1182139.

34. Czaplicki D., Horwacik I., Kowalczyk A., Wieczorek A., Bolek-Marzec K., Balwierz W., Kozik A., Rokita H. New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients. Acta Biochim Pol. 2009;56(3):423–31. PMID:19724779.

35. Valentino L., Moss T., Olson E., Wang H.J., Elashoff R., Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood. 1990;75(7):1564–7. PMID:2317562.

36. Ladisch S., Gillard B. A solvent partition method for microscale ganglioside purifi cation. Anal Biochem. 1985;146(1):220–31. doi:10.1016/0003-2697(85)90419-1. PMID:3993932.

37. Ladisch S., Gillard B. Isolation and purification of gangliosides from plasma. Methods Enzymol. 1987;138:300–6. doi:10.1016/0076-6879(87)38025-5. PMID:3600328.

38. Ledeenr W., Yu R.K. Gangliosides: structures, isolation, and analysis. In: Methods in enzymology. V. Ginsburg (ed.). Vol. 83, Part D. Academic Press, New York, 1982. Pp. 139–191.

39. Terzic T., Cordeau M., Herblot S., Teira P., Cournoyer S., Beaunoyer M., Peuchmaur M., Duval M., Sartelet H. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Pediatr Dev Pathol. 2018;21(4):355–62. doi:10.1177/1093526617723972.

40. Keyel M.E., Reynolds C.P. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 2018;13:1–12. doi:10.2147/BTT.S114530.

41. Mujoo K., Cheresh D.A., Yang H.M., Reisfeld R.A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47(4):1098–104. PMID:3100030.